Next Steps in Research Investigating the Benefits of Aspirin in Patients with Chronic Kidney Disease
November 5th 2021Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses next steps in research investigating the benefits of aspirin in patients with chronic kidney disease.
Implications of Study Results Investigating Long-term Aspirin Use, Kidney Disease Progression
November 5th 2021Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the implications of study results assessing long-term aspirin use and the progression of kidney disease.
Consider Best Sequencing of Agents When Treating Patients With Neuroendocrine Tumors
November 5th 2021Mei Ka Fong, PharmD, BCOP, said that although many potential adverse events are well understood in patients receiving traditional treatments, there are no studies investigating the sequencing of these agents.
Overview of the Results of Treating Carcinoid Crisis Without Perioperative Octreotide
November 5th 2021Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, discusses what the study results demonstrated regarding treating carcinoid crisis without perioperative octreotide for patients with neuroendocrine tumors.
Selecting the Patient Population When Investigating Perioperative Octreotide for Carcinoid Crisis
November 5th 2021Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses the selection of the patient populations included in the study of carcinoid crisis with no perioperative octreotide.
How Chronic Microinflammation Contributes to the Progression of Chronic Diseases
November 4th 2021Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, discusses her presentation at the American Society of Nephrology’s Kidney Week 2021 on the association between long-term aspirin use and the progression of kidney disease.
Disease-Modifying Therapy for Atopic Dermatitis and Unmet Needs in Treatment
November 4th 2021Shannon M. Rotolo, PharmD, BCPS, examines the role dupilimab plays as a disease-modifying therapy for the treatment of moderate-to-severe atopic dermatitis, and Peter Lio, MD, considers the unmet needs that exist within atopic dermatitis therapy.
Next Steps for Research Investigating Adverse Effects With Rosuvastatin Use
November 4th 2021Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses next steps in potential future research avenues following the results of her analysis into the risk of hematuria and proteinuria associated with rosuvastatin use.
Controlling ACE and ARB Dosing Can Benefit Treatment of Chronic Kidney Disease
November 4th 2021Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Implications of Research Assessing Adverse Effects With Rosuvastatin Use
November 4th 2021Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses the results of her research regarding the risks of hematuria and proteinuria with rosuvastatin use.
Why Hematuria, Proteinuria Are Associated With Rosuvastatin Use
November 4th 2021Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.
Overview of Established Risks Associated With Rosuvastatin Use
November 4th 2021Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.
Assessing Octreotide Use in the Treatment of Carcinoid Crises in Patients With Neuroendocrine Tumors
November 4th 2021Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.
Identifying Carcinoid Crises in Patients With Neuroendocrine Tumors Undergoing Operation
November 4th 2021Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses his presentation at the 2021 NANETS Virtual Symposium on a prospective study of carcinoid crisis with no perioperative octreotide.